Danske Bank A S Lowers Position in Merck & Co., Inc. $MRK

Danske Bank A S cut its stake in Merck & Co., Inc. (NYSE:MRK) by 2.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,865,444 shares of the company’s stock after selling 40,586 shares during the quarter. Danske Bank A S’s holdings in Merck & Co., Inc. were worth $196,357,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Danica Pension Livsforsikringsaktieselskab raised its stake in shares of Merck & Co., Inc. by 41.6% in the fourth quarter. Danica Pension Livsforsikringsaktieselskab now owns 191,871 shares of the company’s stock worth $20,196,000 after purchasing an additional 56,400 shares during the last quarter. Mutual Advisors LLC raised its stake in shares of Merck & Co., Inc. by 1.1% in the fourth quarter. Mutual Advisors LLC now owns 78,853 shares of the company’s stock worth $8,300,000 after purchasing an additional 887 shares during the last quarter. Vantage Point Financial LLC purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter worth approximately $272,000. GenTrust LLC raised its stake in shares of Merck & Co., Inc. by 64.4% in the fourth quarter. GenTrust LLC now owns 8,230 shares of the company’s stock worth $873,000 after purchasing an additional 3,223 shares during the last quarter. Finally, Citizens Business Bank raised its stake in shares of Merck & Co., Inc. by 8.8% in the fourth quarter. Citizens Business Bank now owns 49,077 shares of the company’s stock worth $5,166,000 after purchasing an additional 3,962 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock opened at $109.33 on Friday. The business’s fifty day simple moving average is $117.69 and its 200 day simple moving average is $107.39. The firm has a market capitalization of $270.03 billion, a P/E ratio of 15.02, a price-to-earnings-growth ratio of 2.25 and a beta of 0.26. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.Merck & Co., Inc.’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period last year, the company posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 4.89 EPS for the current year.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results and product momentum: Merck beat Q1 revenue and adjusted EPS expectations, driven by continued Keytruda demand and contributions from newer launches (Winrevair reported at ~$525M), which underpin near‑term revenue growth. Merck Sales Beat As Winrevair Hits $525 Million
• Positive Sentiment: Management raised adjusted EPS guidance and emphasized oncology strength: Merck narrowed its 2026 guidance range but lifted its profit outlook on stronger Keytruda and new product trends, a positive for earnings power even as revenue bands were tightened. Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
• Positive Sentiment: Clinical pipeline progress: Merck dosed the first patient in Phase 3 studies of enpatoran for lupus skin manifestations — a near‑term clinical milestone that could add long‑term pipeline value if successful. Merck Announces First Dose in Phase 3 Study with Enpatoran
• Neutral Sentiment: Calls and disclosures available: The full Q1 earnings call transcript and the investor slide deck are posted for deeper review of sales mix, margin drivers and forward guidance assumptions. Q1 2026 Earnings Call Transcript Earnings Presentation
• Neutral Sentiment: Minor analyst estimate moves: Some shops trimmed FY forecasts modestly (e.g., Erste’s slight EPS tweak), indicating traders are tweaking models but not overhauling consensus. MRK Q1 Earnings & Sales Beat; 2026 Sales View Tightened
• Negative Sentiment: One‑time acquisition charge produced a GAAP loss: Merck reported a quarterly loss driven by a Cidara‑related acquisition charge, which suppresses headline earnings and can weigh on near‑term sentiment. Merck posts quarterly loss due to Cidara charge
• Negative Sentiment: Tighter revenue guidance and mixed product trends: Management narrowed the sales range for 2026 and flagged mixed growth among some newer and legacy products, which leaves upside constrained and raises uncertainty about sustained top‑line acceleration. Merck Q1 earnings beat; 2026 guidance narrowed
• Negative Sentiment: Market concerns about future sales erosion: Commentary and coverage highlighted risks from expected declines in certain legacy drugs (HPV vaccine, diabetes medicine) and the company’s efforts to offset those losses, which contributes to investor caution. Merck Stock Falls After Earnings

Insiders Place Their Bets

In other Merck & Co., Inc. news, CMO Chirfi Guindo sold 10,000 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $118.41, for a total value of $1,184,100.00. Following the completion of the sale, the chief marketing officer directly owned 70,615 shares of the company’s stock, valued at $8,361,522.15. This trade represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP David Michael Williams sold 5,000 shares of the firm’s stock in a transaction on Friday, February 6th. The stock was sold at an average price of $121.91, for a total value of $609,550.00. Following the completion of the sale, the executive vice president directly owned 30,838 shares of the company’s stock, valued at $3,759,460.58. This represents a 13.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 320,176 shares of company stock valued at $38,281,735. Company insiders own 0.17% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. JPMorgan Chase & Co. lifted their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. Barclays initiated coverage on Merck & Co., Inc. in a report on Friday, February 20th. They set an “overweight” rating and a $140.00 price target on the stock. TD Cowen lifted their price target on Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a report on Tuesday, January 20th. Finally, Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and a consensus price target of $128.47.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.